Stay updated with breaking news from Agonist. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
BT7480 is the Company's Fourth Product Candidate to Enter the Clinic in the Past Four Years This is Bicycle's First Immuno-oncology Asset to Enter the Clinic Bicycle Therapeutics plc (NASDAQ: BCYC)
TOKYO (dpa-AFX) - Takeda Pharmaceutical Company Limited (TAK) said that a safety signal has emerged in Phase 2 studies of TAK-994, an investigational oral orexin agonist. As an immediate precautionary
Patent protection in U.S. runs through 2037 CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., Aug. 10, 2021(NASDAQ: FSTX) ("F-star" or the "Company"), a clinical-stage biopharmaceutical company dedicated
F-star Therapeutics, Inc.: Study Published in Nature Shows F-Star's STING Agonist SB 11285 Enhances Preclinical Efficacy of Radiation Therapy SB 11285 is a Second Generation STING Agonist Delivered Intravenously CAMBRIDGE, United Kingdom and CAMBRIDGE, Mass., April 19, 2021. The study entitled "STING enhances cell death through regulation of reactive oxygen species and DNA damage" demonstrates that systemic administration of a STING agonist in combination with radiation in a preclinical model enhances local control in Head and Neck Squamous Cell Carcinoma (HNSCC) and suggests that STING expre...
Cleveland BioLabs, Inc: Genome Protection Announces Publication of the Next Generation Deimmunized TLR5 Agonist, GP532 The substantially improved pharmacological profile of GP532 opens new opportunities for broader therapeutic applications of this class of pharmaceuticals BUFFALO, NY / ACCESSWIRE / April 14, 2021 / Genome Protection, Inc. (GPI), a joint venture between Cleveland BioLabs, Inc. (NASDAQ:CBLI) and Everon BioSciences, LLC, an innovative biopharmaceutical company focused on developing medical interventions to prevent and treat aging and age-related diseases, announces a publication...